Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement

Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD dat...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Rajbanshi, Biplab [verfasserIn] Das, Koyeli [verfasserIn] Roy, Debadrita [verfasserIn] Saha, Subhadeep [verfasserIn] Roy, Mahendra Nath [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2022

Schlagwörter:	Alverine citrate Cyclodextrin, Human serum albumin Controlled Drug delivery Inclusion Complex Solubility enhancement

Übergeordnetes Werk:	Enthalten in: Journal of molecular liquids - New York, NY [u.a.] : Elsevier, 1983, 370
Übergeordnetes Werk:	volume:370

DOI / URN:	10.1016/j.molliq.2022.121036

Katalog-ID:	ELV009033114

Internformat


LEADER	01000caa a22002652 4500
001	ELV009033114
003	DE-627
005	20230524151321.0
007	cr uuu---uuuuu
008	230510s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.molliq.2022.121036 \|2 doi
035			\|a (DE-627)ELV009033114
035			\|a (ELSEVIER)S0167-7322(22)02575-2
040			\|a DE-627 \|b ger \|c DE-627 \|e rda
041			\|a eng
082	0	4	\|a 540 \|q DE-600
084			\|a 35.21 \|2 bkl
100	1		\|a Rajbanshi, Biplab \|e verfasserin \|4 aut
245	1	0	\|a Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement
264		1	\|c 2022
336			\|a nicht spezifiziert \|b zzz \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system.
650		4	\|a Alverine citrate
650		4	\|a Cyclodextrin, Human serum albumin
650		4	\|a Controlled Drug delivery
650		4	\|a Inclusion Complex
650		4	\|a Solubility enhancement
700	1		\|a Das, Koyeli \|e verfasserin \|4 aut
700	1		\|a Roy, Debadrita \|e verfasserin \|4 aut
700	1		\|a Saha, Subhadeep \|e verfasserin \|4 aut
700	1		\|a Roy, Mahendra Nath \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Journal of molecular liquids \|d New York, NY [u.a.] : Elsevier, 1983 \|g 370 \|h Online-Ressource \|w (DE-627)302469664 \|w (DE-600)1491496-7 \|w (DE-576)259483915 \|x 1873-3166 \|7 nnns
773	1	8	\|g volume:370
912			\|a GBV_USEFLAG_U
912			\|a SYSFLAG_U
912			\|a GBV_ELV
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_224
912			\|a GBV_ILN_370
912			\|a GBV_ILN_374
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2807
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
936	b	k	\|a 35.21 \|j Lösungen \|j Flüssigkeiten \|x Physikalische Chemie
951			\|a AR
952			\|d 370

Indexfelder

author_variant	b r br k d kd d r dr s s ss m n r mn mnr
matchkey_str	article:18733166:2022----::xlrn2icuinopeeoccoetisnatsamdcavrnctaeoehnigiaal
hierarchy_sort_str	2022
bklnumber	35.21
publishDate	2022
allfields	10.1016/j.molliq.2022.121036 doi (DE-627)ELV009033114 (ELSEVIER)S0167-7322(22)02575-2 DE-627 ger DE-627 rda eng 540 DE-600 35.21 bkl Rajbanshi, Biplab verfasserin aut Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system. Alverine citrate Cyclodextrin, Human serum albumin Controlled Drug delivery Inclusion Complex Solubility enhancement Das, Koyeli verfasserin aut Roy, Debadrita verfasserin aut Saha, Subhadeep verfasserin aut Roy, Mahendra Nath verfasserin aut Enthalten in Journal of molecular liquids New York, NY [u.a.] : Elsevier, 1983 370 Online-Ressource (DE-627)302469664 (DE-600)1491496-7 (DE-576)259483915 1873-3166 nnns volume:370 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2807 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 35.21 Lösungen Flüssigkeiten Physikalische Chemie AR 370
spelling	10.1016/j.molliq.2022.121036 doi (DE-627)ELV009033114 (ELSEVIER)S0167-7322(22)02575-2 DE-627 ger DE-627 rda eng 540 DE-600 35.21 bkl Rajbanshi, Biplab verfasserin aut Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system. Alverine citrate Cyclodextrin, Human serum albumin Controlled Drug delivery Inclusion Complex Solubility enhancement Das, Koyeli verfasserin aut Roy, Debadrita verfasserin aut Saha, Subhadeep verfasserin aut Roy, Mahendra Nath verfasserin aut Enthalten in Journal of molecular liquids New York, NY [u.a.] : Elsevier, 1983 370 Online-Ressource (DE-627)302469664 (DE-600)1491496-7 (DE-576)259483915 1873-3166 nnns volume:370 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2807 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 35.21 Lösungen Flüssigkeiten Physikalische Chemie AR 370
allfields_unstemmed	10.1016/j.molliq.2022.121036 doi (DE-627)ELV009033114 (ELSEVIER)S0167-7322(22)02575-2 DE-627 ger DE-627 rda eng 540 DE-600 35.21 bkl Rajbanshi, Biplab verfasserin aut Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system. Alverine citrate Cyclodextrin, Human serum albumin Controlled Drug delivery Inclusion Complex Solubility enhancement Das, Koyeli verfasserin aut Roy, Debadrita verfasserin aut Saha, Subhadeep verfasserin aut Roy, Mahendra Nath verfasserin aut Enthalten in Journal of molecular liquids New York, NY [u.a.] : Elsevier, 1983 370 Online-Ressource (DE-627)302469664 (DE-600)1491496-7 (DE-576)259483915 1873-3166 nnns volume:370 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2807 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 35.21 Lösungen Flüssigkeiten Physikalische Chemie AR 370
allfieldsGer	10.1016/j.molliq.2022.121036 doi (DE-627)ELV009033114 (ELSEVIER)S0167-7322(22)02575-2 DE-627 ger DE-627 rda eng 540 DE-600 35.21 bkl Rajbanshi, Biplab verfasserin aut Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system. Alverine citrate Cyclodextrin, Human serum albumin Controlled Drug delivery Inclusion Complex Solubility enhancement Das, Koyeli verfasserin aut Roy, Debadrita verfasserin aut Saha, Subhadeep verfasserin aut Roy, Mahendra Nath verfasserin aut Enthalten in Journal of molecular liquids New York, NY [u.a.] : Elsevier, 1983 370 Online-Ressource (DE-627)302469664 (DE-600)1491496-7 (DE-576)259483915 1873-3166 nnns volume:370 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2807 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 35.21 Lösungen Flüssigkeiten Physikalische Chemie AR 370
allfieldsSound	10.1016/j.molliq.2022.121036 doi (DE-627)ELV009033114 (ELSEVIER)S0167-7322(22)02575-2 DE-627 ger DE-627 rda eng 540 DE-600 35.21 bkl Rajbanshi, Biplab verfasserin aut Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system. Alverine citrate Cyclodextrin, Human serum albumin Controlled Drug delivery Inclusion Complex Solubility enhancement Das, Koyeli verfasserin aut Roy, Debadrita verfasserin aut Saha, Subhadeep verfasserin aut Roy, Mahendra Nath verfasserin aut Enthalten in Journal of molecular liquids New York, NY [u.a.] : Elsevier, 1983 370 Online-Ressource (DE-627)302469664 (DE-600)1491496-7 (DE-576)259483915 1873-3166 nnns volume:370 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2807 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393 35.21 Lösungen Flüssigkeiten Physikalische Chemie AR 370
language	English
source	Enthalten in Journal of molecular liquids 370 volume:370
sourceStr	Enthalten in Journal of molecular liquids 370 volume:370
format_phy_str_mv	Article
bklname	Lösungen Flüssigkeiten
institution	findex.gbv.de
topic_facet	Alverine citrate Cyclodextrin, Human serum albumin Controlled Drug delivery Inclusion Complex Solubility enhancement
dewey-raw	540
isfreeaccess_bool	false
container_title	Journal of molecular liquids
authorswithroles_txt_mv	Rajbanshi, Biplab @@aut@@ Das, Koyeli @@aut@@ Roy, Debadrita @@aut@@ Saha, Subhadeep @@aut@@ Roy, Mahendra Nath @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	302469664
dewey-sort	3540
id	ELV009033114
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV009033114</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230524151321.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230510s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.molliq.2022.121036</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV009033114</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-7322(22)02575-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.21</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rajbanshi, Biplab</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alverine citrate</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cyclodextrin, Human serum albumin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Controlled Drug delivery</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inclusion Complex</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Solubility enhancement</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Das, Koyeli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roy, Debadrita</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Saha, Subhadeep</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roy, Mahendra Nath</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of molecular liquids</subfield><subfield code="d">New York, NY [u.a.] : Elsevier, 1983</subfield><subfield code="g">370</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)302469664</subfield><subfield code="w">(DE-600)1491496-7</subfield><subfield code="w">(DE-576)259483915</subfield><subfield code="x">1873-3166</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_374</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2807</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.21</subfield><subfield code="j">Lösungen</subfield><subfield code="j">Flüssigkeiten</subfield><subfield code="x">Physikalische Chemie</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">370</subfield></datafield></record></collection>
author	Rajbanshi, Biplab
spellingShingle	Rajbanshi, Biplab ddc 540 bkl 35.21 misc Alverine citrate misc Cyclodextrin, Human serum albumin misc Controlled Drug delivery misc Inclusion Complex misc Solubility enhancement Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement
authorStr	Rajbanshi, Biplab
ppnlink_with_tag_str_mv	@@773@@(DE-627)302469664
format	electronic Article
dewey-ones	540 - Chemistry & allied sciences
delete_txt_mv	keep
author_role	aut aut aut aut aut
collection	elsevier
remote_str	true
illustrated	Not Illustrated
issn	1873-3166
topic_title	540 DE-600 35.21 bkl Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement Alverine citrate Cyclodextrin, Human serum albumin Controlled Drug delivery Inclusion Complex Solubility enhancement
topic	ddc 540 bkl 35.21 misc Alverine citrate misc Cyclodextrin, Human serum albumin misc Controlled Drug delivery misc Inclusion Complex misc Solubility enhancement
topic_unstemmed	ddc 540 bkl 35.21 misc Alverine citrate misc Cyclodextrin, Human serum albumin misc Controlled Drug delivery misc Inclusion Complex misc Solubility enhancement
topic_browse	ddc 540 bkl 35.21 misc Alverine citrate misc Cyclodextrin, Human serum albumin misc Controlled Drug delivery misc Inclusion Complex misc Solubility enhancement
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of molecular liquids
hierarchy_parent_id	302469664
dewey-tens	540 - Chemistry
hierarchy_top_title	Journal of molecular liquids
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)302469664 (DE-600)1491496-7 (DE-576)259483915
title	Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement
ctrlnum	(DE-627)ELV009033114 (ELSEVIER)S0167-7322(22)02575-2
title_full	Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement
author_sort	Rajbanshi, Biplab
journal	Journal of molecular liquids
journalStr	Journal of molecular liquids
lang_code	eng
isOA_bool	false
dewey-hundreds	500 - Science
recordtype	marc
publishDateSort	2022
contenttype_str_mv	zzz
author_browse	Rajbanshi, Biplab Das, Koyeli Roy, Debadrita Saha, Subhadeep Roy, Mahendra Nath
container_volume	370
class	540 DE-600 35.21 bkl
format_se	Elektronische Aufsätze
author-letter	Rajbanshi, Biplab
doi_str_mv	10.1016/j.molliq.2022.121036
dewey-full	540
author2-role	verfasserin
title_sort	exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, alverine citrate for enhancing bioavailability and sustained dischargement
title_auth	Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement
abstract	Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system.
abstractGer	Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system.
abstract_unstemmed	Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system.
collection_details	GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_224 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2807 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4313 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4393
title_short	Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement
remote_bool	true
author2	Das, Koyeli Roy, Debadrita Saha, Subhadeep Roy, Mahendra Nath
author2Str	Das, Koyeli Roy, Debadrita Saha, Subhadeep Roy, Mahendra Nath
ppnlink	302469664
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1016/j.molliq.2022.121036
up_date	2024-07-06T21:45:22.297Z
_version_	1803867727905947648
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV009033114</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230524151321.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230510s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.molliq.2022.121036</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV009033114</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-7322(22)02575-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.21</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rajbanshi, Biplab</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Solubility development of supramolecular host–guest interaction between Alverine citrate with α and β-cyclodextrins were studied throughout the article. 2:1 host to guest stoichiometry of the inclusion complexation in the solution phase were confirmed by the Job’s plot. The IR, DSC, SEM and PXRD data turn out to be supportive about the phenomenon, inclusion complexation. Association constants and thermodynamic parameters of the inclusion complexes were obtained using UV–vis and spectrofluorometric measurement. The mechanism of inclusion complexation was explored by 1H and 2D ROESY NMR spectroscopy. Binding ability of the drug molecule, Alverine citrate with the HSA and the controlled release of the drug molecule from inclusion complexes were studied at PH-7.4 by spectrofluorimetricaly. Studied phenomenon thus develops the solubility of merely soluble drug into water, consequently makes bioavailable and enriches the drug delivery system.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Alverine citrate</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cyclodextrin, Human serum albumin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Controlled Drug delivery</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inclusion Complex</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Solubility enhancement</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Das, Koyeli</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roy, Debadrita</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Saha, Subhadeep</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roy, Mahendra Nath</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of molecular liquids</subfield><subfield code="d">New York, NY [u.a.] : Elsevier, 1983</subfield><subfield code="g">370</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)302469664</subfield><subfield code="w">(DE-600)1491496-7</subfield><subfield code="w">(DE-576)259483915</subfield><subfield code="x">1873-3166</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_374</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2807</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.21</subfield><subfield code="j">Lösungen</subfield><subfield code="j">Flüssigkeiten</subfield><subfield code="x">Physikalische Chemie</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">370</subfield></datafield></record></collection>
score	7.399289

Nicht das Richtige dabei?

Schreiben Sie uns!

Exploring 2:1 inclusion complexes of cyclodextrins and antispasmodics, Alverine citrate for enhancing bioavailability and sustained dischargement

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?